Why is Eli Lilly stock rallying today?

Eli Lilly's phase 3 trial for retatrutide, a weight-loss drug, showed significant weight reduction (17.6% to 25%) and improvements in obesity-related conditions. The drug targets three hormone receptors. Eli Lilly plans to seek FDA approval, but no timeline is set. Unapproved versions of the drug have been linked to deaths, according to reports.

Eli Lilly has started construction on a $6.5bn plant in Houston to produce Foundayo, its oral GLP-1 treatment for type 2 diabetes and obesity. The facility will create 600 jobs and is part of a $12.5m investment in workforce training. Foundayo is under regulatory review in over 40 countries, with a global rollout planned for 2027. This is the largest active pharmaceutical ingredient project in Texas history, according to Governor Greg Abbott.

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

Pennsylvania sued 17 pharma companies and PBMs, including Eli Lilly, Sanofi, and Novo Nordisk, for allegedly colluding to raise insulin prices by over 1,000% since the mid-2000s. The lawsuit claims this harmed 1.3 million diabetics in the state, forcing many to ration insulin. The state seeks restitution and penalties under consumer protection laws.

Eli Lilly (LLY) stock trades at a premium, with growth expectations tied to its weight-loss drug Foundayo. Foundayo is selling in the U.S. and U.K., with 36,000 prescribers and 30% market share of new U.S. patients. Lilly's obesity drugs Mounjaro and Zepbound generated $14.9B of its $23.0B Q2 2026 revenue. Foundayo's expansion and regulatory decisions could drive future growth.

Eli Lilly's lebrikizumab (Ebglyss) showed significant improvement in skin clearance, itch, and pain for hand and foot eczema in a phase 3b trial, with 53% of patients achieving clear or almost clear skin at 16 weeks vs 27% on placebo. The trial also reported rapid itch relief and high patient satisfaction. Safety was consistent with known profiles. Presented at EADV Congress 2026.